GlassScriptPhysician profile
Sara Stephenson
NPI 1497717557
$1,027.36
in general payments reported to CMS, 2019-2025
24 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $67.35 · 2021: $180 · 2022: $92.12 · 2023: $180 · 2024: $164 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $173.28 | 2019-2023 | Lo Loestrin Fe, Orilissa, Oriahnn |
| Exeltis, USA INC. | $146.14 | 2020-2024 | Slynd |
| Biogen, INC. | $123.99 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $100.41 | 2020-2025 | |
| Medtronic, INC. | $52.60 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $47.91 | 2022-2023 | |
| Coopersurgical, INC. | $44.81 | 2020-2024 | Paragard T 380a |
| Pfizer INC. | $34.24 | 2021-2023 | |
| Organon LLC | $28.78 | 2025 | Nexplanon |
| Avion Pharmaceuticals | $27.27 | 2019-2023 | Balcoltra |
| Sumitomo Pharma America, INC. | $26.16 | 2025 | Myfembree |
| Hologic Sales and Service, LLC | $24.02 | 2025 | Fluent Fluid Management System, Myosure Tissue Removal Device, Novasure |
| Alexion Pharmaceuticals, INC. | $21.23 | 2022 | |
| Daiichi Sankyo INC. | $20.93 | 2021 | |
| Agile Therapeutics, INC. | $19.04 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.18 | 2024 | Gardasil, Gardasil 9 |
| Millicent US INC | $17.19 | 2025 | Femlyv |
| Astellas Pharma US INC | $16.40 | 2024 | Veozah |
| Duchesnay USA Incorporated | $15.77 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.88 | 2021 | |
| Minerva Surgical, INC | $14.45 | 2021 | |
| Abbott Laboratories | $14.31 | 2019 | |
| Allergan, INC. | $13.11 | 2019 | |
| Lupin INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Stephenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.